European Society for Medical Oncology, 2024 - Thoracic oncology
Implementation of Medical Remote Monitoring in Thoracic Oncology: A Real-World Study of 835 Patients Across 51 Centers in France and Belgium.
Dec 4, 2025
2 minutes
Authors
Laurent Greillier 1, Hervé Pegliasco 2, Simon Deshayes 3, Jean-Marc Vernejoux 4, Dimitri Leite Ferreira 3, Benjamin Huret 5, Claire Tissot 6, Myriam Delaunay 7, Otilia Stamerra 8, Maximilien Autheman 9, Claudia Parisi 10, Benjamin Besse 10, Julien Mazières 11.
Affiliation
1. Assistance Publique des Hôpitaux de Marseille, Marseille, France ; 2. Hôpital Européen de Marseille, Marseille, France ; 3. Centre Hospitaler Universitaire Caen Normandie , Caen, France ; 4. Clinique La Croix du Sud, Quint-Fonsegrives, France ; 5. Hôpital Privé La Louvière, Lille, France ; 6. Hôpital Privé de la Loire, Saint-Etienne, France ; 7. Clinique de l’Union, Saint-Jean, France ; 8. Hôpital Privé Armand Brillard, Nogent-sur-Marne, France ; 9. Resilience, Paris, France ; 10. Gustave Roussy,Villejuif, France ; 11. Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Introduction
Medical remote monitoring based on ePROs (electronic Patient-Reported Outcomes) has demonstrated clinical and organizational benefits through Phase III randomized controlled clinical trials[1-4]. These benefits include:
- Symptom control,
- Quality of life,
- Increased relative dose intensity,
- Reduction in the number of hospitalizations,
- Prolongation of overall survival.
Consequently, in 2022, ESMO published its recommendations regarding medical remote monitoring for routine clinical practice during anti-cancer treatments[5].
However, patient adherence and the benefits of remote monitoring in thoracic oncology remain unknown. This study presents and analyzes the deployment of remote monitoring in this setting and its impacts.
Poster presented at the 2024 ESMO (European Society of Medical Oncology) Congress.
Sources
1. Mir O, Ferrua M, Fourcade A, et al. Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. Nat Med.2022;28(6):1224-1231.
2. Basch E, Schrag D, Henson S, et al. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022;327(24):2413-2422.
3. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol. 2019 Feb20;37(6):528.
4. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA.2017;318(2):197-198.
5. Di Maio M, Basch E, Denis F, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33(9):878-892. doi:10.1016/j.annonc.2022.04.007.
